1. Home
  2. ATXG vs VIVS Comparison

ATXG vs VIVS Comparison

Compare ATXG & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATXG

Addentax Group Corp.

HOLD

Current Price

$0.27

Market Cap

4.6M

ML Signal

HOLD

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$1.83

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATXG
VIVS
Founded
2014
2007
Country
China
United States
Employees
N/A
9
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATXG
VIVS
Price
$0.27
$1.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
88.9K
77.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$1.42
52 Week High
$1.86
$5.30

Technical Indicators

Market Signals
Indicator
ATXG
VIVS
Relative Strength Index (RSI) 32.55 43.20
Support Level N/A $1.75
Resistance Level $0.49 $2.14
Average True Range (ATR) 0.03 0.13
MACD -0.00 -0.02
Stochastic Oscillator 13.04 2.08

Price Performance

Historical Comparison
ATXG
VIVS

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: